Defence Therapeutics Receives USPTO Allowance for ADC Patent Application

Defence Therapeutics has received a Notice of Allowance from the USPTO for its patent application covering next-generation ADC technology. The patent will provide the company with potential market exclusivity until 2043 for its proprietary second-generation Accum-based ADCs. This milestone builds on Defence's established patent portfolio for its foundational Accum technology. The company's ADC platform technology represents a significant advancement in oncotherapy and targeted drug delivery.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has received a Notice of Allowance from the USPTO for its patent application covering next-generation ADC technology. This significant milestone grants the company potential market exclusivity until 2043 for its proprietary second-generation Accum-based ADCs [2].

The patent builds upon Defence's established patent portfolio for its foundational Accum technology. The company's ADC platform technology represents a significant advancement in oncotherapy and targeted drug delivery. Defence Therapeutics is a leading biotechnology company specializing in advanced endosomal escape technologies, with a focus on developing next-generation radio-immuno-conjugate and ADC products using its proprietary Accum® technology [2].

The new patent strengthens Defence Therapeutics' position in the competitive biotechnology landscape and positions the company at the forefront of innovation in the ADC market. The company's expansion into the Boston-Cambridge area further underscores its commitment to advancing cutting-edge research and development in one of the world's foremost biotech clusters [2].

This development is a testament to Defence Therapeutics' commitment to pushing the boundaries of targeted cancer therapies. The company's Accum® technology enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, increasing efficacy and potency against cancer [2].

With this patent, Defence Therapeutics is well-positioned to continue its mission of advancing the Accum® platform for next-generation ADCs. The company's strategic expansion and technological advancements highlight its potential to make a significant impact on the oncology market.

References:
[1] https://finance.yahoo.com/news/obi-pharma-enters-adc-collaboration-070000695.html
[2] https://www.biospace.com/press-releases/defence-therapeutics-opens-u-s-laboratory-in-boston-cambridge-biotech-hub